This Pharma Billionaire Is Developing A Cannabis Painkiller To Replace Dangerous Opioids

Key Concepts

• Cannabinoid-based painkiller (Ver01)
• Chronic pain treatment
• Opioid replacement
• Pharmaceutical drug approval process (EMA, FDA)
• Clinical trials (Phase 3)
• Non-opioid pain relievers
• Cannabis industry regulations
• Pharmaceutical entrepreneurship

Vertanle's Cannabis-Based Painkiller (Ver01)

Vertanle, a Munich-based pharmaceutical company, is developing Ver01, a cannabinoid-based extract, as a treatment for chronic pain. The goal is for Ver01 to become an approved medicine, initially in the European Union and eventually in the United States. Ver01 is designed to relieve pain without causing a significant "high" in patients, as the dosage contains low levels of cannabinoids, including THC. The drug will be prescribed by physicians and covered by insurance, not sold in cannabis dispensaries.

Clemens Fischer and Futuru Group

Clemens Fischer, a medical doctor with an MBA from Harvard, is the founder of Vertanle. He runs a mini-empire through Futuru Group, a Munich-based holding company with approximately 20 drug and R&D companies. Fischer has a history of building and selling over-the-counter drug and supplement companies, accumulating a $1 billion fortune. He views the recreational marijuana industry as a "shiny object to be avoided," preferring the regulated pharmaceutical route.

Regulatory Strategy and Investment

Fischer is pursuing drug approval through the European Medicines Agency (EMA) and, eventually, the US Food and Drug Administration (FDA). He has invested over $250 million of his own money in Vertanle, which he founded in 2017 with Madina Holofhelder. Vertanle has a cannabis cultivation site and pharmaceutical manufacturing plant in Denmark.

Clinical Trial Results and Approval Timeline

Vertanle has successfully completed Phase 3 clinical trials in Germany. The data indicates that Ver01 is more effective than opioid painkillers with fewer side effects, including no evidence of addiction. The company anticipates a decision from German and Austrian authorities later this year or early next year, which would allow them to begin selling the medicine. Following this, they plan to apply for broader authorization across the EU and hope to launch Phase 3 trials in the US in 2026.

The Need for Non-Opioid Pain Relievers

The video highlights the urgent need for non-opioid pain relievers due to the opioid epidemic in the US, fueled by drugs like Oxycontin. In 2023, there were 125 million opioid prescriptions written in the US, representing a market worth approximately $20 billion in annual sales, according to President's Research. Opioid overdoses claimed the lives of over 80,000 people in the US last year. The FDA has announced plans to accelerate the approval of non-opioid drugs for chronic pain.

Competition and Market Opportunity

Jouavex, a non-opioid drug approved by the FDA for acute pain in January 2025, generated $13 million in sales in its first six months. Fischer believes Vertanle can capture a portion of the multi-billion dollar chronic pain market by offering a cannabis-based alternative to opioids.

Notable Quotes

• Clemens Fischer: "I usually end up with the boring things no one wants to do."
• Clemens Fischer: "We believe that we will be the first nonopiate chronic pain treatment worldwide."

Conclusion

Vertanle is pursuing a regulated pharmaceutical approach to develop and market a cannabis-based painkiller, Ver01, as a safer and more effective alternative to opioids for chronic pain management. The company has completed Phase 3 trials and is awaiting regulatory approval in Europe, with plans to expand to the US market. The development of non-opioid pain relievers is a critical need due to the opioid crisis, and Vertanle aims to address this need with its innovative cannabis-based drug.